USPSTF: Evidence is insufficient to support lipid disorder screening in asymptomatic kids

There is not yet enough evidence to adequately assess the benefit-harm balance of screening for lipid disorders in asymptomatic children and adolescents aged 20 years or younger, according to a statement from the U.S. Preventive Services Task Force.
The I draft recommendation statement aligns with the task force’s 2016 decision and calls for more research on the balance of risks and benefits when it comes to screening and treating for lipid disorders in children and adolescents who do not already show symptoms or have a cholesterol disorder.
The task force based its recommendation on a

There is not yet enough evidence to adequately assess the benefit-harm balance of screening for lipid disorders in asymptomatic children and adolescents aged 20 years or younger, according to a statement from the U.S. Preventive Services Task Force.
The I draft recommendation statement aligns with the task force’s 2016 decision and calls for more research on the balance of risks and benefits when it comes to screening and treating for lipid disorders in children and adolescents who do not already show symptoms or have a cholesterol disorder.
The task force based its recommendation on a